
Laurus Labs (LAURUSLABS) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
15.7B
Gross Profit
9.3B
59.39%
Operating Income
2.7B
16.90%
Net Income
1.6B
10.30%
EPS (Diluted)
₹3.02
Balance Sheet Metrics
Total Assets
93.4B
Total Liabilities
47.3B
Shareholders Equity
46.0B
Debt to Equity
1.03
Cash Flow Metrics
Revenue & Profitability Trend
Laurus Labs Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 55.1B | 50.0B | 60.1B | 48.9B | 47.2B |
Cost of Goods Sold | 25.4B | 25.0B | 28.4B | 22.5B | 22.0B |
Gross Profit | 29.7B | 25.0B | 31.7B | 26.4B | 25.3B |
Gross Margin % | 53.9% | 50.0% | 52.8% | 54.0% | 53.5% |
Operating Expenses | |||||
Research & Development | 553.0M | 437.6M | 255.9M | 294.7M | 172.9M |
Selling, General & Administrative | 2.5B | 2.0B | 1.8B | 1.6B | 1.4B |
Other Operating Expenses | 9.3B | 8.8B | 7.9B | 5.7B | 4.7B |
Total Operating Expenses | 12.4B | 11.2B | 10.0B | 7.6B | 6.3B |
Operating Income | 6.3B | 3.9B | 12.9B | 11.7B | 13.5B |
Operating Margin % | 11.4% | 7.9% | 21.5% | 24.0% | 28.5% |
Non-Operating Items | |||||
Interest Income | 151.7M | 56.1M | 45.6M | 17.2M | 13.1M |
Interest Expense | 2.1B | 1.7B | 1.2B | 757.6M | 552.8M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 4.8B | 2.4B | 11.1B | 10.8B | 13.0B |
Income Tax | 1.3B | 681.5M | 3.1B | 2.5B | 3.2B |
Effective Tax Rate % | 26.8% | 28.8% | 28.2% | 23.2% | 24.4% |
Net Income | 3.6B | 1.6B | 7.9B | 8.3B | 9.8B |
Net Margin % | 6.5% | 3.2% | 13.2% | 17.0% | 20.8% |
Key Metrics | |||||
EBITDA | 10.6B | 7.8B | 15.6B | 14.1B | 15.6B |
EPS (Basic) | ₹6.65 | ₹2.98 | ₹14.69 | ₹15.42 | ₹18.36 |
EPS (Diluted) | ₹6.64 | ₹2.97 | ₹14.64 | ₹15.35 | ₹18.28 |
Basic Shares Outstanding | 539152333 | 538749879 | 537730888 | 536813916 | 535748294 |
Diluted Shares Outstanding | 539152333 | 538749879 | 537730888 | 536813916 | 535748294 |
Income Statement Trend
Laurus Labs Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 995.4M | 1.4B | 456.7M | 755.8M | 484.6M |
Short-term Investments | 505.3M | 115.3M | 27.9M | 5.9M | 390.7M |
Accounts Receivable | 20.1B | 16.6B | 15.8B | 13.5B | 13.1B |
Inventory | 19.4B | 18.5B | 16.8B | 17.6B | 15.8B |
Other Current Assets | 22.1M | 9.6M | 23.1M | 11.2M | 9.8M |
Total Current Assets | 43.3B | 38.3B | 34.6B | 33.4B | 30.7B |
Non-Current Assets | |||||
Property, Plant & Equipment | 1.9B | 1.8B | 1.3B | 1.4B | 551.6M |
Goodwill | 5.1B | 5.1B | 5.1B | 5.0B | 5.0B |
Intangible Assets | 193.2M | 190.2M | 129.3M | 108.3M | 93.2M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 1.3B | 648.8M | 1.2B | 598.9M | 958.9M |
Total Non-Current Assets | 50.0B | 45.5B | 42.0B | 36.2B | 26.8B |
Total Assets | 93.4B | 83.9B | 76.6B | 69.7B | 57.5B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 9.6B | 10.5B | 7.1B | 8.8B | 11.8B |
Short-term Debt | 20.6B | 17.2B | 12.2B | 11.4B | 10.3B |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 347.2M | 488.4M | 630.0M | 478.9M | 295.2M |
Total Current Liabilities | 35.4B | 31.1B | 24.3B | 26.8B | 24.6B |
Non-Current Liabilities | |||||
Long-term Debt | 7.1B | 8.6B | 8.0B | 6.4B | 4.6B |
Deferred Tax Liabilities | 318.7M | 570.4M | 824.5M | 691.1M | 191.8M |
Other Non-Current Liabilities | 3.5B | 1.1B | 1.3B | 670.3M | 718.4M |
Total Non-Current Liabilities | 11.9B | 11.6B | 11.8B | 9.3B | 6.9B |
Total Liabilities | 47.3B | 42.7B | 36.1B | 36.1B | 31.5B |
Equity | |||||
Common Stock | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B |
Retained Earnings | 36.3B | 33.1B | 33.0B | 26.2B | 18.8B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 46.0B | 41.2B | 40.5B | 33.6B | 26.0B |
Key Metrics | |||||
Total Debt | 27.6B | 25.8B | 20.2B | 17.8B | 14.8B |
Working Capital | 7.9B | 7.2B | 10.3B | 6.6B | 6.2B |
Balance Sheet Composition
Laurus Labs Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 4.8B | 2.4B | 11.1B | 10.8B | 13.0B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 102.3M | 109.2M | 74.8M | 66.4M | 28.9M |
Working Capital Changes | -2.8B | -3.6B | -1.5B | -404.0M | -11.5B |
Operating Cash Flow | 4.1B | 532.4M | 11.1B | 11.3B | 2.1B |
Investing Activities | |||||
Capital Expenditures | -5.4B | -6.8B | -9.9B | -8.8B | -6.8B |
Acquisitions | -1.1B | -1.5B | -223.0M | -276.0M | -2.6B |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -6.9B | -8.3B | -10.0B | -9.2B | -9.4B |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -431.3M | -861.8M | -1.1B | -858.6M | -750.4M |
Debt Issuance | 1.8B | 3.6B | 3.8B | 4.1B | 4.0B |
Debt Repayment | -3.2B | -2.2B | -2.5B | -1.7B | -957.3M |
Financing Cash Flow | 2.8B | 4.6B | 1.2B | 1.9B | 3.2B |
Free Cash Flow | -393.5M | -126.2M | 37.4M | 342.6M | 442.3M |
Net Change in Cash | 42.6M | -3.2B | 2.3B | 4.1B | -4.1B |
Cash Flow Trend
Laurus Labs Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
90.88
Forward P/E
36.79
Price to Book
10.37
Price to Sales
7.83
PEG Ratio
0.07
Profitability Ratios
Profit Margin
8.58%
Operating Margin
16.90%
Return on Equity
7.79%
Return on Assets
3.84%
Financial Health
Current Ratio
1.22
Debt to Equity
60.05
Beta
0.36
Per Share Data
EPS (TTM)
₹9.46
Book Value per Share
₹82.94
Revenue per Share
₹110.17
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
lauruslabs | 464.1B | 90.88 | 10.37 | 7.79% | 8.58% | 60.05 |
Sun Pharmaceutical | 3.9T | 37.88 | 5.45 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 70.42 | 10.88 | 14.64% | 23.89% | 0.03 |
Cipla | 1.3T | 23.42 | 4.05 | 16.85% | 19.62% | 1.40 |
Torrent | 1.2T | 61.35 | 16.15 | 25.18% | 16.92% | 42.81 |
Dr. Reddy's | 1.0T | 18.52 | 3.00 | 17.71% | 16.99% | 13.75 |
Financial data is updated regularly. All figures are in the company's reporting currency.